[Form 4] Emergent Biosolutions, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Donald W. DeGolyer, a director of Emergent BioSolutions (EBS), sold 7,844 shares of common stock on 08/12/2025 at an exact price of $8.6475 per share to satisfy tax obligations arising from the settlement of vested restricted stock units (RSUs) on 05/22/2025. After this tax-withholding sale the reporting person directly beneficially owns 137,659 shares. The filing lists the transaction code "S" and provides the explanation that the sale was executed solely to satisfy tax withholding related to the RSU settlement.

Positive

• Transaction fully disclosed on Form 4 with explanation tying the sale to RSU tax withholding
• Reporting person retains 137,659 shares after the tax-withholding sale, preserving significant direct ownership

Negative

• None.

Insights

Financial Analyst

TL;DR: Director sold 7,844 shares to cover RSU taxes; transaction is routine and has limited ownership impact.

The sale reduced the director's share count by 7,844 at a price of $8.6475 per share and is explicitly described as a tax-withholding transaction tied to RSU vesting on 05/22/2025. Post-transaction direct ownership remains at 137,659 shares, indicating continued meaningful alignment with shareholders. There is no information in the filing suggesting discretionary or opportunistic selling; this is a standard compensation-related transaction with minimal likely market or governance implications.

Corporate Governance Expert

TL;DR: Form 4 disclosure documents a routine RSU tax-withholding sale and meets reporting transparency requirements.

The Form 4 clearly identifies the reporting person as a director and discloses the sale as tied to settlement of vested RSUs, fulfilling Section 16 reporting obligations. The explicit explanation and the exact sale price ($8.6475) limit ambiguity about the nature of the transaction. This disclosure practice aligns with standard governance expectations for timely reporting of insider equity transactions.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DeGolyer Donald W

(Last) (First) (Middle)

300 PROFESSIONAL DR

(Street)

GAITHERSBURG MD 20879

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Emergent BioSolutions Inc. [ EBS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/12/2025	08/12/2025	S		7,844(1)	D	$8.6475(2)	137,659	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares sold by the Reporting Person to satisfy the Reporting Person's tax obligations resulting from the settlement of vested RSUs on May 22, 2025.

2. All shares sold at an exact price of $8.6475.

Remarks:

	/s/ Richard S. Lindahl, Attorney-in-fact	08/13/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the Emergent BioSolutions (EBS) insider sell?

The insider sold 7,844 shares of Emergent BioSolutions common stock.

Why were the 7,844 shares sold by the EBS director?

The sale was made to satisfy tax obligations resulting from the settlement of vested RSUs on 05/22/2025.

At what price were the shares sold in the EBS Form 4?

All shares were sold at an exact price of $8.6475 per share.

How many EBS shares does the reporting person own after the sale?

After the transaction the reporting person directly beneficially owns 137,659 shares.

Who reported the transaction on behalf of the insider in the EBS filing?

The Form 4 was signed by an attorney-in-fact on behalf of the reporting person, as shown in the filing.